Physician profile
Bowei Tan
NPI 1477936086
$2,014.05
in general payments reported to CMS, 2019-2025
19 companies · $24.85 in 2025
The $24.85 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $434 · 2021: $373 · 2022: $439 · 2023: $348 · 2024: $139 · 2025: $24.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $489.03 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $435.84 | 2020-2024 | |
| Pfizer INC. | $270.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $102.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.28 | 2019-2024 | Jardiance |
| Abbvie INC. | $97.12 | 2021-2023 | Dalvance |
| Gilead Sciences, INC. | $96.68 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.93 | 2022-2024 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.01 | 2019 | |
| Allergan, INC. | $59.57 | 2020 | |
| Portola Pharmaceuticals, LLC | $40.59 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.30 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $36.88 | 2021-2022 | |
| Chiesi USA, INC. | $21.06 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.35 | 2023 | Inpefa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $19.01 | 2020 | |
| Shire North American Group INC | $16.42 | 2019 | |
| Glaxosmithkline, LLC. | $15.87 | 2023 | Trelegy Ellipta |
| Mylan Specialty L.P. | $14.43 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bowei Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.